SK Plasma operates plasma fractionation facilities that convert donated human plasma into high‑purity therapeutics such as albumin, immunoglobulin, clotting factors, and antithrombin III.
Funding
$49.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with conditions such as hypoalbuminemia, immune deficiencies, hemophilia, or thrombin deficiency require high‑purity plasma‑derived therapeutics, but reliable access to safe, consistently manufactured blood products is limited by complex collection, fractionation, and stringent regulatory requirements.
Solution
SK Plasma operates dedicated plasma fractionation facilities that transform donated human plasma into a portfolio of clinically essential products—including albumin, immunoglobulin, clotting factors, and antithrombin III. The company employs multi‑stage purification, virus inactivation, and rigorous quality‑control protocols to ensure product safety and potency. Its integrated SCADA and EMS monitoring systems maintain continuous oversight of process parameters, reducing contamination risk and enhancing batch consistency. By adhering to cGMP standards and obtaining national marketing authorizations, SK Plasma delivers these therapeutics to hospitals and clinics domestically and to more than 20 overseas markets. The firm also offers contract manufacturing and technology transfer services, enabling partners to establish local plasma processing capabilities.
Target Audience
Primary customers are hospitals, specialty clinics, and national blood services that treat patients requiring plasma‑derived therapeutics, as well as pharmaceutical partners seeking contract manufacturing or technology‑transfer solutions.
Features
- Multi‑step plasma fractionation with at least two virus inactivation/removal stages for high safety assurance
- Real‑time process control via SCADA and environmental monitoring (EMS) to ensure consistent product quality
- cGMP‑certified production lines for albumin, immunoglobulin, clotting factors, and antithrombin III
- Certified clean‑room facilities achieving top‑tier international green building standards (energy, CO₂, water reductions)
- Global distribution network supplying products to over 20 countries with compliance to local regulatory frameworks
- Contract manufacturing and technology‑transfer programs for partner plasma‑derived product development